Related Experiment Video

Updated: Aug 16, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

A bifunctional targeted peptide that blocks HER-2 tyrosine kinase and disables mitochondrial function in

Valeria R Fantin1, Marcelo J Berardi, Holger Babbe

  • 1Department of Genetics, Harvard Medical School and Howard Hughes Medical Institute, Boston, Massachusetts 02215, USA. vfantin@genetics.med.harvard.edu

Cancer Research
|August 3, 2005
PubMed

Insights

Researchers developed a novel bifunctional peptide, BHAP, targeting the HER-2 oncoprotein. This peptide selectively induces apoptosis in HER-2-overexpressing cancer cells, including Herceptin-resistant types, and inhibits tumor growth.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • The HER-2 oncoprotein is frequently overexpressed in various human cancers, presenting a significant therapeutic target.
  • Inhibiting the HER-2 receptor tyrosine kinase is a key strategy in current cancer research.
  • Resistance to existing therapies like Herceptin necessitates novel treatment approaches.

Purpose of the Study:

  • To engineer a novel bifunctional peptide, BHAP, for targeted cancer therapy.
  • To assess the efficacy of BHAP in selectively inducing apoptosis in HER-2-overexpressing cancer cells.
  • To evaluate the in vivo antitumor activity of BHAP against HER-2-positive xenografts.

Main Methods:

  • Design and engineering of a bifunctional peptide (BHAP) with HER-2 targeting and mitochondriotoxic domains.
  • In vitro assessment of BHAP's ability to induce apoptosis in HER-2-overexpressing cancer cell lines, including Herceptin-resistant ones.
  • In vivo evaluation of BHAP's efficacy in slowing tumor growth in SCID mice bearing HER-2-overexpressing human mammary xenografts.

Main Results:

  • BHAP demonstrated biological activity and selectively triggered apoptosis in HER-2-overexpressing cancer cells in vitro.
  • The peptide was effective against cancer cells resistant to Herceptin.
  • BHAP significantly slowed the growth of HER-2-overexpressing human mammary xenografts in vivo.

Conclusions:

  • BHAP is a potent bifunctional peptide capable of targeting and neutralizing HER-2-overexpressing cancer cells.
  • This approach offers a promising strategy for overcoming resistance to current HER-2 targeted therapies.
  • The development of tailored chimeric peptides targeting overexpressed receptors holds potential for broad cancer treatment applications.

More Related Videos

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...